Assessment of Circulating CCR6 Level in Acute Myocardial Infarction and its Association with Disease Severity

Cardiovasc Hematol Agents Med Chem. 2023;21(3):223-231. doi: 10.2174/1871525721666230120160717.

Abstract

Background: Acute myocardial infarction (AMI) pathophysiology is mediated by systemic, intraplaque myocardial inflammatory processes that occur mainly due to coronary artery thrombosis in an atherosclerotic plaque area. The G-protein-coupled chemokine receptor (Ccr6) is displayed on the surface of many types of leukocytes, that have been found in atherosclerotic plaques. It is a novel mediator of inflammation and immune response.

Objectives: To determine CCR6 lymphocyte expression in AMI patients and its association with disease severity using the Gensini scoring system.

Methods: 25 AMI patients and 25 controls underwent flow cytometry to determine the percentage of circulating CCR6+ lymphocytes. To forecast AMI and determine how CCR6 expression relates to it, multivariate logistic regression analysis was used.

Results and discussion: There was a higher percentage of CCR6+ lymphocyte expression in AMI patients than in controls. In addition, CCR6 showed a significant positive correlation with the Gensini score (GS) in the AMI group then with the degree of coronary artery disease (CAD).

Conclusion: The chemokine receptor CCR6 is an independent biomarker for AMI and mayplay a role as a mediator of T lymphocyte recruitment, which is associated with coronary lesion destabilization.

Keywords: CCR6; acute myocardial infarction; atherosclerosis; gensini score; logistic regression analysis; lymphocyte.

MeSH terms

  • Coronary Artery Disease* / complications
  • Coronary Artery Disease* / diagnosis
  • Humans
  • Myocardial Infarction* / complications
  • Myocardial Infarction* / diagnosis
  • Patient Acuity
  • Plaque, Atherosclerotic* / complications
  • Receptors, CCR6
  • Receptors, Chemokine

Substances

  • Receptors, Chemokine
  • CCR6 protein, human
  • Receptors, CCR6